Reports Q4 revenue $6.6M vs $2.9M last year. “2025 was a very productive year for the Lineage team,” stated Brian M. Culley, Lineage CEO. “Our mission is to pioneer the emerging field of allogeneic cell therapy outside of oncology by applying our proprietary cell manufacturing technology platform, AlloSCOPE, to the production and transplantation of differentiated cell types, which are intended to replace the cells which a patient has lost, or lost function of, due to various conditions.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX:
- Options Volatility and Implied Earnings Moves Today, March 05, 2026
- LCTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Lineage Cell Therapeutics management to meet with B, Riley
- De-Risked Cell Therapy Platform and Roche Partnership Momentum Underpin Buy Rating on Lineage (LCTX)
- Lineage Cell Therapeutics receives iPSC line from Factor Bioscience